Djibouti

Population 2018 <1 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>2.5 (1.9–3.2)</td>
<td>260 (199–329)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.09 (0.062–0.12)</td>
<td>9.4 (6.5–13)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence</td>
<td>0.12 (0.063–0.21)</td>
<td>13 (6.6–22)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.28 (0.17–0.38)</td>
<td>28 (18–40)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.019 (0.013–0.027)</td>
<td>2 (1.3–2.8)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed
- % children aged 0-14 years
- % women
- % men

Total TB incidence 2.5 (1.9–3.2)

HIV-positive TB incidence 0.09 (0.062–0.12)

MDR-RR-TB incidence 0.12 (0.063–0.21)

HIV-negative TB mortality 0.28 (0.17–0.38)

HIV-positive TB mortality 0.019 (0.013–0.027)

HIV-negative TB mortality 0.26 (0.17–0.38)

HIV-positive TB mortality 0.019 (0.013–0.027)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases 4.7% (2.8–7.7)

Previously treated cases 9.7% (4.5–18)

TB case notifications, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed
- % children aged 0-14 years
- % women
- % men

Total new and relapse 1 997

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 80% (63–100)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018 12% (7–17)

TB/HIV care in new and relapse TB patients, 2018

Number (%) patients with known HIV status who are HIV-positive

- on antiretroviral therapy

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance

- New cases 67%

- Previously treated cases 97%

Laboratory-confirmed cases* MDR/RR-TB: 67, XDR-TB: 7


MDR-RR-TB tests for resistance to second-line drugs 27

Treatment success rate and cohort size

Success Cohort

New and relapse cases registered in 2017 85% 1 059

Previously treated cases, excluding relapse registered in 2017 0% 1

MDR-RR-TB cases started on second-line treatment in 2016 69% 71

XDR-TB cases started on second-line treatment in 2016 67% 6

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 13% (12–15)

TB financing, 2019

National TB budget (US$ millions) 1.3

Funding source: domestic, 41% international, 59% unfunded

Ranges represent uncertainty intervals
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
Calculated for pulmonary cases only
Includes cases with unknown previous TB treatment history
Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed